Prestige Consumer Healthcare (NYSE:PBH) VP Jeffrey Zerillo Sells 346 Shares

Key Points

• VP Jeffrey Zerillo sold 346 shares on May 5 at an average price of $55.32 for $19,140.72, trimming his stake by 0.77% to 44,334 shares; the sale was executed under a pre-arranged Rule 10b5-1 trading plan.
• Prestige's latest quarter slightly missed expectations (EPS $1.14 vs. $1.16 expected; revenue $283.44M vs. $286.93M), yet the company set FY2026 guidance at 4.54 EPS, while analysts maintain a consensus "Hold" rating with a $76.50 price target.
• Shares recently traded at $54.20 (one-year range $51.24–$89.37) and the company has a market capitalization of $2.56 billion with institutional ownership around 99.95%.

Prestige Consumer Healthcare Inc. (NYSE:PBH - Get Free Report) VP Jeffrey Zerillo sold 346 shares of the company's stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $55.32, for a total value of $19,140.72. Following the sale, the vice president directly owned 44,334 shares of the company's stock, valued at $2,452,556.88. The trade was a 0.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jeffrey Zerillo also recently made the following trade(s):

• On Wednesday, February 11th, Jeffrey Zerillo sold 1,000 shares of Prestige Consumer Healthcare stock. The shares were sold at an average price of $65.93, for a total transaction of $65,930.00.

Prestige Consumer Healthcare Stock Performance

Shares of NYSE PBH traded down $1.55 during trading hours on Wednesday, hitting $54.20. 519,183 shares of the stock were exchanged, compared to its average volume of 461,679. Prestige Consumer Healthcare Inc. has a one year low of $51.24 and a one year high of $89.37. The company's 50 day moving average is $60.83 and its 200 day moving average is $62.03. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.11 and a quick ratio of 1.93. The firm has a market capitalization of $2.56 billion, a P/E ratio of 14.34, a P/E/G ratio of 1.65 and a beta of 0.40.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings results on Thursday, February 5th. The company reported $1.14 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.16 by ($0.02). The firm had revenue of $283.44 million for the quarter, compared to the consensus estimate of $286.93 million. Prestige Consumer Healthcare had a net margin of 16.90% and a return on equity of 12.02%. The firm's revenue was down 2.4% on a year-over-year basis. During the same quarter last year, the company earned $1.22 earnings per share. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. On average, research analysts expect that Prestige Consumer Healthcare Inc. will post 4.54 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have commented on PBH. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Prestige Consumer Healthcare in a research report on Tuesday, April 21st. Jefferies Financial Group lowered their price objective on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a "hold" rating on the stock in a research note on Friday, January 30th. Three analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Prestige Consumer Healthcare has an average rating of "Hold" and a consensus price target of $76.50.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Large investors have recently added to or reduced their stakes in the company. Massachusetts Financial Services Co. MA boosted its stake in shares of Prestige Consumer Healthcare by 10.2% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 650,793 shares of the company's stock valued at $40,147,000 after purchasing an additional 60,496 shares in the last quarter. Nordea Investment Management AB increased its position in shares of Prestige Consumer Healthcare by 547.4% during the 4th quarter. Nordea Investment Management AB now owns 615,215 shares of the company's stock worth $37,811,000 after purchasing an additional 520,186 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Prestige Consumer Healthcare by 30.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 459,228 shares of the company's stock valued at $28,656,000 after purchasing an additional 106,224 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its position in Prestige Consumer Healthcare by 1.3% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,613,460 shares of the company's stock valued at $98,776,000 after buying an additional 21,085 shares in the last quarter. Finally, Tributary Capital Management LLC boosted its position in Prestige Consumer Healthcare by 157.3% in the third quarter. Tributary Capital Management LLC now owns 379,410 shares of the company's stock valued at $23,675,000 after buying an additional 231,969 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company's stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women's health.

Key brands in Prestige's portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women's health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.